It would be up to the proponents to decide what they want to do, what their market strategy would be. The NRCan program supporting alternative technologies will support them to get to that phase so they will have the technology ready so that all the regulatory approvals will be in place, and then they will have their strategy about how they want to bring that technology forward. In the supplementary estimates (A) funding is going to AECL including to maintain operations of the NRU reactor to produce the current medical isotopes until October 2016.
On June 2nd, 2015. See this statement in context.